Improving progression-free and overall survival in patients with cancer: A potential role for bisphosphonates

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.

Original languageEnglish (US)
Pages (from-to)749-762
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number5
DOIs
StatePublished - Apr 1 2011

Fingerprint

Diphosphonates
Disease-Free Survival
Neoplasms
Multiple Myeloma
Expert Testimony
Therapeutics
Neoplasm Metastasis
Bone and Bones
Survival
Growth

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{40694e646f6f4afea7d6a377e139ef11,
title = "Improving progression-free and overall survival in patients with cancer: A potential role for bisphosphonates",
abstract = "Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.",
author = "Allan Lipton",
year = "2011",
month = "4",
day = "1",
doi = "10.1517/14656566.2011.538384",
language = "English (US)",
volume = "12",
pages = "749--762",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

Improving progression-free and overall survival in patients with cancer : A potential role for bisphosphonates. / Lipton, Allan.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 5, 01.04.2011, p. 749-762.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Improving progression-free and overall survival in patients with cancer

T2 - A potential role for bisphosphonates

AU - Lipton, Allan

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.

AB - Introduction: Bisphosphonates are a well-established therapy for patients with multiple myeloma or bone metastases from advanced cancers and are used routinely to delay the onset and reduce the risk of skeletal-related events. Emerging evidence indicates that they also may provide additional anticancer benefits. These developments warrant reappraisal of their role in patients with cancer and reevaluation of optimal therapeutic regimens. Areas covered: This article reviews the evidence of the anticancer activity of bisphosphonates in patients with solid tumors or multiple myeloma. The underlying mechanisms of the anticancer activity of bisphosphonates are elucidated from preclinical and translational data that show that bisphosphonates suppress tumor growth and survival, inhibit tumor-mediated angiogenesis, or stimulate host anticancer immune response. These data also provide insights into the potential for therapeutic combinations. Preclinical and clinical data relating to the anticancer effects of bisphosphonates are reviewed by cancer type. Expert opinion: Future trials of bisphosphonates in cancer patients will explore the underlying mechanism of the anticancer benefit in greater detail and attempt to examine critically the potential clinical benefit in individual cancer types in early/advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=79952609241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952609241&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.538384

DO - 10.1517/14656566.2011.538384

M3 - Review article

C2 - 21247359

AN - SCOPUS:79952609241

VL - 12

SP - 749

EP - 762

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -